Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HMPL-453 tartrate alone and in combination with chemotherapy or toripalimab in advanced solid tumors
CTR20212423Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fanregratinib in Nonhematologic neoplasms, intrahepatic cholangiocarcinoma (ICC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, transitional cell carcinoma (TCC), sponsored by HUTCHMED. Started Jan 2022; status: completed.
02
Drugs
fanregratinib
03
Conditions
Nonhematologic neoplasmsintrahepatic cholangiocarcinoma (ICC)gastric adenocarcinomagastroesophageal junction adenocarcinomatransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20212423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212423.